Skip Navigation Links
A Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata.
Overall Recruitment Status: Active, currently enrolling
Official Title
A Multicenter, Open-Label, Extension Study to Assess the Long-Term Safety and Efficacy of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata.
Region Sponsors
California - Northern
Concert Pharmaceuticals
Acronym KP IRB No.
CTP-543 1405545
Study Type Phase
Clinical Trial Phase II
Study Population Description
(Adult, Older Adult) Male and Female with Alopecia Areata.
The overall objectives of the study are to evaluate long-term safety of CTP-543 and to assess long-term effects of CTP-543 on treating hair loss in adult patients with chronic, moderate to severe alopecia areata.
Detailed Description
Gender Age Limit
Male & Female 18 - 65 years
Inclusion Criteria
  • Have completed 24 weeks of treatment in a previous qualifying CTP-543 clinical trial
Exclusion Criteria
  • Active scalp inflammation, psoriasis, or seborrheic dermatitis requiring topical treatment to the scalp, significant trauma to the scalp, or untreated actinic keratosis
  • Females who are nursing, pregnant, or planning to become pregnant while in the study, and for 30 days after last dose of study medication
  • Donation of blood at any point throughout the study and for 30 days after last dose of study medication

Keywords and/or Specific Medical Conditions
  • Alopecia
  • Pathological Conditions, Anatomical
  • Alopecia Areata
  • Pathology
  • CP543.5001
  • Skin Diseases
  • Hair Diseases
  • Dermatology
  • Hypotrichosis
KP Clinical Facility
  • San Francisco Medical Center
Clinical Area
  • Dermatology
  • Pathology

Principal Investigator:
Paradi Mirmirani, MD
Contact Information:
- Daisy Mendoza-Zepeda
-Central Valley-Manteca

Do you want to receive
Email Alerts?

Sign Up Here!

Regional Research Sites: